Aquestive Therapeutics Announces Chief Legal Officer Transition and New Appointment

summarizeSummary

Aquestive Therapeutics announced a change in its Chief Legal Officer and Chief Compliance Officer roles, with Lori J. Braender stepping down and Thomas A. Zalewski appointed as her successor, accompanied by a significant equity vesting for the departing officer.

check_boxKey Events

• Executive Departure

  Lori J. Braender is stepping down as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, but will remain as Corporate Secretary.

• Significant Equity Vesting

  Ms. Braender will receive full and immediate vesting of all unvested stock options, RSUs, SARs, and other equity awards on May 7, 2026, as part of her separation agreement.

• New Executive Appointment

  Thomas A. Zalewski has been appointed as the new Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, bringing extensive experience in life sciences law.

• Inducement Equity Grant

  Mr. Zalewski will receive an inducement grant of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options, vesting over three years.

auto_awesomeAnalysis

Aquestive Therapeutics is undergoing a significant leadership transition with the departure of its Chief Legal Officer and Chief Compliance Officer, Lori J. Braender, from her executive roles. The immediate vesting of all her unvested equity awards as part of her separation package represents a notable compensation event for the company. The appointment of Thomas A. Zalewski as the new Chief Legal Officer and Chief Compliance Officer provides continuity in a critical function, especially as the company navigates recent FDA approval delays and increased net losses.